Tonix Pharmaceuticals Holding (TNXP) announced that it is committed to meeting potential increased demand for Tosymra, or sumatriptan, nasal spray 10 mg after GlaxoSmithKline’s (GSK) planned discontinuation of Imitrex, or sumatriptan, nasal spray 5 mg and 20 mg products after January, 2024. Drug shortages have presented an ongoing challenge for the U.S. healthcare system, reaching near-record levels2 in recent months, causing treatment delays and rationing. Tonix is ready to step in to alleviate potential shortages in sumatriptan, a widely used treatment option for acute migraine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNXP:
- Tonix Pharmaceuticals reports Phase 2 results of Long COVID candidate TNX-102
- Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox
- Tonix Pharmaceuticals announces results of pre-IND meeting with FDA for TNX-801
- Tonix Pharmaceuticals to Present at the August Virtual Investor Summit
- Tonix Pharmaceuticals initiates Phase 1 trial of TNX-1500